Compare Johnson & Johnson (JNJ) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Johnson & Johnson trades at $250.27 (market cap $598.96B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.64. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | VNQI | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $50.76 |
52-Week Low | $164.36 | $43.26 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.5, down 0.48% today, with technical indicators showing a bullish trend but neutral oscillators. The ETF provides diversified international real estate exposure across 30+ countries with a low 0.12% expense ratio and a 4.6% dividend yield. Recent news highlights its role as a cost-effective diversifier compared to domestic REIT ETFs, though it has lagged in total returns over the past five years.
The outlook remains cautiously optimistic as global real estate transaction volumes are expected to rise over 10% in 2026 amid stabilizing rates. Key opportunities include international diversification and attractive yield, while risks involve currency fluctuations and slower international market recovery compared to U.S. real estate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
